Time filter

Source Type

United Kingdom

The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.

NeRRe Therapeutics | Date: 2013-10-09

This invention relates to the new use of the compound (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of pruritus and to combinations for such a use.

NeRRe Therapeutics | Entity website

NeRRe Therapeutics Ltd, a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists, is pleased to announce that Dr Mary Kerr is joining the company as CEO at the beginning of October Read more

First Clinical Trial for NeRRe Therapeutics Stevenage, UK, 23 January 2014. NeRRe Therapeutics Ltd, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, is pleased to announce the start of a Phase II study of the novel NK-1 receptor antagonist orvepitant ...

NeRRe Therapeutics | Entity website

Our Focus NeRRes main focus is on NT-814 our dual NK-1, 3 antagonist, as a non-hormonal oral treatment for sex hormone related conditions in Women. Novel emerging science points to the role of the NK-3 (and -1) receptor system in a range of Womens Heath indications, by virtue of the modulatory role it plays on the centrally located KNDy (kisspeptin-neurokinin B-dynorphin) neurone network ...

Discover hidden collaborations